- $24.59bn
- $21.44bn
- $8.26m
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Roivant's experimental lung disease drug meets goals in mid-stage study (updated)
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Roivant Sciences jumps after lung disease drug meets main goal in mid-stage study
Roivant's experimental lung disease drug meets goals in mid-stage study
Roivant Sciences jumps after lung disease drug meets main goal in mid-stage study
Brief: Roivant Announces Positive Results From PHocus Study Of Mosliciguat In Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) And Unveils Ongoing Phase 3 PHrontier Study
Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month (updated)
Roivant sets price for new rare disease drug Lisraya at $35,000 a month
US FDA approves Roivant-Priovant's skin and muscle disease drug (updated)
US FDA approves Roivant-Priovant's skin disease drug
Brief: FDA Approves First Oral Drug Indicated To Treat Dermatomyositis In Adults
Roivant Sciences Ltd reports results for the quarter ended June 30 - Earnings Summary
Corrected: Switzerland's Roivant Q1 loss widens
Brief: Roivant Sciences Q1 Adjusted Net Income USD -290.606 Million Vs. IBES Estimate USD -192.3 Million